An early-career Cleveland Clinic researcher has devised a multipronged strategy that integrates advanced computational and experimental approaches to dementia research. The work has attracted $16 million in external grant funding in 2023 alone.
Read MoreCleveland Clinic Treats First Patient With Investigational Gene Therapy for Hypertrophic Cardiomyopathy
The case launches the first human trial of a novel adenovirus-based therapy designed as a one-time injection to treat a common form of HCM.
Parkinson’s Disease Research in Women (Podcast)
Our latest Neuro Pathways podcast explores observed gender differences in PD and shares how we’re using a novel female-tailored patient questionnaire to better understand the disease in women.
Genetics of Parkinson’s Disease in Latino Populations (Podcast)
Little is known about the genes that may influence Parkinson’s disease risk in Latinos, but a multinational research consortium is working to change that. Hear from the consortium’s U.S. coordinator in our latest podcast episode.
The Cost of ‘Free’: Advising Patients About Sponsored Genetic Testing
Sponsored genetic testing appears to be an attractive option for both patient and clinician, but experts say there are nonfinancial disadvantages that can create ethical challenges. Here’s what to know and how to counsel patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Quantum Computing Debuts at Cleveland Clinic
The world’s first quantum computer devoted to healthcare research is now operational at Cleveland Clinic, part of a landmark partnership with IBM called the Discovery Accelerator that will use advanced computing technologies to hasten biomedical innovations.
Determining Autism, Cancer Risk in Patients with PTEN Hamartoma Tumor Syndrome
Studying the relationship between autism spectrum disorder and cancer in individuals affected by PTEN hamartoma tumor syndrome is the subject of a new $2 million grant awarded from the National Institutes of Health to Charis Eng, MD, PhD, Chair of the Genomic Medicine Institute.
Deep Learning Framework Unveiled for Identifying Risk Genes and Drug Targets in Alzheimer’s Disease
Application of the novel framework has identified the dyslipidemia medication gemfibrozil as a candidate drug to reduce Alzheimer’s disease risk.
Transcriptomics-Based Study Suggests Metformin Is Repurposable for Atrial Fibrillation
A broad research effort involving network-medicine methodologies and pharmacoepidemiologic analysis has pinpointed the diabetes medication metformin as a leading antiarrhythmic candidate drug.
Big Patient Data Analyses Pinpoint Telmisartan as a Candidate Drug for Alzheimer’s in Black Adults
A combination of pharmacoepidemiologic studies and Mendelian randomization genetic analysis revealed preferential protection in Black but not white individuals. The findings support ongoing studies of telmisartan for Alzheimer’s, particularly in racially diverse cohorts.
Altered Mental Status in a Man With Metabolic Syndrome
While pharmacogenomic testing can flag patients at risk for events from drug-drug or drug-gene interactions, careful monitoring of patients’ drug regimens for potential interactions is an effective and often more feasible strategy.